Develops immunotherapies for cancer treatment, focusing on enhancing immune responses against tumor cells.
MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for inflammatory diseases. At the forefront of its pipeline is Sonelokimab, a novel investigational Nanobody therapy designed to target and treat inflammation. The company is currently advancing Sonelokimab through Phase II clinical trials for several conditions, including hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, and radiographic axial spondyloarthritis.
Founded in 2021 and headquartered in Zug, Switzerland, MoonLake Immunotherapeutics leverages cutting-edge science to address unmet medical needs. The company's commitment to innovation is exemplified by its focus on Nanobody technology, which offers a unique approach to treating complex inflammatory conditions. MoonLake's research and development efforts are dedicated to providing patients with more effective and targeted therapeutic options.
In addition to its clinical advancements, MoonLake Immunotherapeutics is building a robust infrastructure to support its growth and global reach. The company is actively engaged in collaborations and partnerships to enhance its scientific capabilities and expedite the development of its therapies. With a strong foundation and a clear vision, MoonLake Immunotherapeutics is poised to make significant contributions to the field of immunotherapy and improve the lives of patients worldwide.